## Narjust Duma

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6134920/publications.pdf

Version: 2024-02-01

		1306789	1125271
16	327	7	13
papers	citations	h-index	g-index
1.6	1.6	1.6	<b>500</b>
16	16	16	583
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Knowledge, Practice, and Attitudes of Physicians in Low- and Middle-Income Countries on Fertility and Pregnancy-Related Issues in Young Women With Breast Cancer. JCO Global Oncology, 2022, 8, e2100153.	0.8	6
2	HOLA COVID-19 Study: Evaluating the Impact of Caring for Patients With COVID-19 on Cancer Care Delivery in Latin America. JCO Global Oncology, 2022, 8, e2100251.	0.8	1
3	Disparities in Cancer Care and Scientific Knowledge in Hispanic/Latinx People in the United States. JCO Oncology Practice, 2022, 18, 367-369.	1.4	O
4	Proyecto ELEVAR: Evaluating the Latinx Experience With the Health Care System Through Variables on Access and Resources. JCO Oncology Practice, 2022, 18, e814-e826.	1.4	3
5	Disparities in Cardio-Oncology Care in the Hispanic/Latinx Population. JCO Oncology Practice, 2022, 18, 404-409.	1.4	3
6	Dónde Están? Latinx/Hispanic Representation in the Oncology Workforce: Present and Future. JCO Oncology Practice, 2022, 18, 388-395.	1.4	6
7	The Problem of Hispanic/Latinx Under-Representation in Cancer Clinical Trials. JCO Oncology Practice, 2022, 18, 380-384.	1.4	14
8	It Can Wait. Oncologist, 2021, 26, 439-440.	1.9	0
9	COVID-19 and Global Oncology: A Year in Review. JCO Global Oncology, 2021, 7, 797-801.	0.8	4
10	Male breast cancer in the United States: Treatment patterns and prognostic factors in the 21st century. Cancer, 2020, 126, 26-36.	2.0	82
11	The Dragon. Oncologist, 2020, 25, 903-904.	1.9	O
12	Gender differences in publication rates in oncology: Looking at the past, present, and future. Cancer, 2020, 126, 2759-2761.	2.0	13
13	It Is Time to Talk About Fertility and Immunotherapy. Oncologist, 2020, 25, 277-278.	1.9	42
14	Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal?. Oncologist, 2019, 24, e1148-e1155.	1.9	81
15	Characterization of Comorbidities Limiting the Recruitment of Patients in Early Phase Clinical Trials. Oncologist, 2019, 24, 96-102.	1.9	35
16	Representation of Minorities and Elderly Patients in Multiple Myeloma Clinical Trials. Oncologist, 2018, 23, 1076-1078.	1.9	37